Seer (NASDAQ:SEER) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Key Points

• Seer missed quarterly expectations: The company reported an adjusted loss of $0.31 per share, $0.04 worse than analysts’ estimate, while revenue of $3.10 million fell short of the $3.55 million consensus.
• Profitability remains weak: Seer posted a negative 26.58% return on equity and a negative net margin of 464.78%, highlighting continued operating losses.
• Analyst sentiment is mixed but leans positive: The stock has a consensus “Buy” rating and a $4.00 average price target, although one analyst maintained a “Sell” rating. Institutional investors own 75.20% of the shares.

Seer (NASDAQ:SEER - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.04), FiscalAI reports. Seer had a negative return on equity of 26.58% and a negative net margin of 464.78%.The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.55 million.

Seer Stock Performance

NASDAQ SEER remained flat at $2.16 on Tuesday. 199,128 shares of the company's stock traded hands, compared to its average volume of 644,225. The business has a 50-day moving average of $1.94 and a two-hundred day moving average of $1.88. The company has a market capitalization of $118.76 million, a PE ratio of -1.74 and a beta of 1.55. Seer has a fifty-two week low of $1.55 and a fifty-two week high of $2.41.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Seer by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,221,404 shares of the company's stock worth $4,820,000 after acquiring an additional 18,760 shares during the period. Bridgeway Capital Management LLC lifted its stake in Seer by 15.5% during the 2nd quarter. Bridgeway Capital Management LLC now owns 837,443 shares of the company's stock valued at $1,792,000 after acquiring an additional 112,100 shares during the period. Geode Capital Management LLC lifted its stake in Seer by 16.5% during the 2nd quarter. Geode Capital Management LLC now owns 509,727 shares of the company's stock valued at $1,091,000 after acquiring an additional 72,265 shares during the period. Jane Street Group LLC boosted its holdings in shares of Seer by 33.3% in the 1st quarter. Jane Street Group LLC now owns 254,174 shares of the company's stock valued at $430,000 after acquiring an additional 63,432 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Seer by 2.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 235,485 shares of the company's stock valued at $431,000 after acquiring an additional 6,304 shares during the last quarter. 75.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. TD Cowen upgraded shares of Seer to a "strong-buy" rating in a report on Monday, April 13th. Canaccord Genuity Group began coverage on shares of Seer in a research note on Monday, May 4th. They issued a "buy" rating and a $4.00 price objective for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Seer in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Seer currently has a consensus rating of "Buy" and an average target price of $4.00.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer's platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company's flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source